Health and Healthcare

Will Celgene Become the Next $100 Billion Biotech Stock?

Does Celgene Corporation (NASDAQ: CELG) have what it takes to make it to a $100 billion market cap? Some analysts would think so, following the favorable release of this biotech giant’s earnings.

The company reported its third-quarter earnings Thursday morning of $0.97 in earnings per share and $1.98 billion in revenue against Thomson Reuters consensus earnings estimates of $0.95 in earnings per share and $1.96 billion in revenue. Celgene reported a 37% increase in profit from increased sales of its multiple myeloma medicine Revlimid. The company posted a net profit of $508 million compared to $372 million in the third quarter of the previous year.

Celgene also went out and raised its outlook for 2014 earnings to the range of $3.65 to $3.70 in earnings per share from $3.60 to $3.65 in earnings per share. It also said that revenue for the 2014 full year was expected to exceed its previous forecast of $7.6 billion.

Analysts will likely be tweaking their estimates higher after this report. With biotech being a hotbed for investors, one has to wonder if price targets will be raised in the week ahead as well. Two recent analyst calls were seen as follows:

  • BofA Merrill Lynch initiated its coverage of Celgene with a Buy rating and price target of $112 (Oct. 1).
  • RBC Capital Markets upgraded Celgene to an Outperform rating and raised its price target to $115 from $100 (Sept. 29).

Now, what about where that $100 billion market cap comes into play? Nomura has a Buy rating for Celgene and the highest price target among analysts of $128. The highest price target from this group would put the company at just over $100 billion, but we would note that Celgene shares would have to rise roughly 25% to hit this mark. Celgene currently has a market cap of roughly $80 billion.

Shares of Celgene were recently trading up almost 6% at $100.40. With an hour and a half left in trading the company has moved over 7 million shares. The company has a consensus analyst price target of $105.03 and a 52-week trading range of $66.85 to $100.91.

And to think that the markets were nearing a panic just a week ago. Had we asked you about this a week ago it might have sounded like blasphemy. Celgene shares saw a selling climax low last week of $83.16 — and now the stock is over $100!.

Find a Qualified Financial Advisor (Sponsor)

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.